Bordetella pertussis pathogenesis: Current and future challenges

Nature Reviews Microbiology

Volumn 12, Issue 4, 2014, Pages 274-288

  Melvin, Jeffrey A ^a   Scheller, Erich V ^a   Miller, Jeff F ^b   Cotter, Peggy A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE TOXIN; BACTERIAL PROTEIN; BORDETELLA VIRULENCE FACTOR; CYTOTOXIN; DERMONECROTIC TOXIN; FILAMENTOUS HAEMAGGLUTININ.; HEMAGGLUTININ; LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; TRACHEAL CYTOTOXIN; UNCLASSIFIED DRUG;

BACTERIAL VIRULENCE; BORDETELLA PERTUSSIS; FIMBRIA; HUMAN; PERTUSSIS; PHENOTYPE; PHYLOGENOMICS; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; TYPE III SECRETION SYSTEM; VACCINATION;

BIOMEDICAL RESEARCH; BORDETELLA PERTUSSIS; COMMUNICABLE DISEASES, EMERGING; HUMANS; MICROBIOLOGY; PERTUSSIS VACCINE; VIRULENCE; VIRULENCE FACTORS; WHOOPING COUGH;

EID: 84896388487     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro3235     Document Type: Review

References (199)

1. de Greeff, S. C. et al. Pertussis disease burden in the household: how to protect young infants. Clin. Infect. Dis. 50, 1339-1345 (2010).
2. Bordet, J. & Gengou, O. Le microbe de la coqueluche. Ann. I'Institut Pasteur 20, 731-741 (In French) (1906).
3. Cherry, J. D. Why do pertussis vaccines fail? Pediatrics 129, 968-970 (2012).
4. Diavatopoulos, D. A. et al. Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog. 1, e45 (2005).
5. Park, J. et al. Comparative genomics of the classical Bordetella subspecies: the evolution and exchange of virulence-associated diversity amongst closely related pathogens. BMC Genomics 13, 545 (2012).
6. Goodnow, R. A. Biology of Bordetella bronchiseptica. Microbiol. Rev. 44, 722-738 (1980). (Pubitemid 11176208)
7. Centers for Disease, Control & Prevention in Epidemiology and Prevention of Vaccine-Preventable Diseases. 215-232 (Public Health Foundation, 2012).
8. American, Academy of Pediatrics in Red Book: 2012 Report of the Committee on Infectious Diseases. 553-566 (American Academy of Pediatrics, 2012).
9. Edwards, J. A., Groathouse, N. A. & Boitano, S. Bordetella bronchiseptica adherence to cilia is mediated by multiple adhesin factors and blocked by surfactant protein A. Infect. Immun. 73, 3618-3626 (2005). (Pubitemid 40745906)
10. Paddock, C. D. et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin. Infect. Dis. 47, 328-338 (2008). (Pubitemid 352013513)
11. Preston, A. & Maskell, D. J. A new era of research into Bordetella pertussis pathogenesis. J. Infect. 44, 13-16 (2002). (Pubitemid 34567625)
12. Poland, G. A. Pertussis outbreaks and pertussis vaccines: new insights, new concerns, new recommendations? Vaccine 30, 6957-6959 (2012).
13. Fisman, D. N. et al. Pertussis resurgence in Toronto, Canada: a population-based study including test-incidence feedback modeling. BMC Publ. Health 11, 694 (2011).
14. Hong, J. Y. Update on pertussis and pertussis immunization. Kor. J. Pediatr. 53, 629-633 (2010).
15. Rohani, P., Zhong, X. & King, A. A. Contact network structure explains the changing epidemiology of pertussis. Science 330, 982-985 (2010).
16. Witt, M. A., Katz, P. H. & Witt, D. J. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin. Infect. Dis. 54, 1730-1735 (2012).
17. Witt, M. A., Arias, L., Katz, P. H., Truong, E. T. & Witt, D. J. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin. Infect. Dis. 56, 1248-1254 (2013).
18. Clark, T. A. & Bobo, N. CDC update on pertussis surveillance and Tdap vaccine recommendations. NASN Sch. Nurse 27, 297-300 (2012).
19. Carbonetti, N. H. Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol. 5, 455-469 (2010).
20. Locht, C., Coutte, L. & Mielcarek, N. The ins and outs of pertussis toxin. FEBS J. 278, 4668-4682 (2011).
21. Decker, K. B., James, T. D., Stibitz, S. & Hinton, D. M. The Bordetella pertussis model of exquisite gene control by the global transcription factor BvgA. Microbiology 158, 1665-1676 (2012).
22. de Gouw, D., Diavatopoulos, D. A., Bootsma, H. J., Hermans, P. W. & Mooi, F. R. Pertussis: a matter of immune modulation. FEMS Microbiol. Rev. 35, 441-474 (2011).
23. Higgs, R., Higgins, S. C., Ross, P. J. & Mills, K. H. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol. 5, 485-500 (2012).
24. Locht, C. & Mielcarek, N. New pertussis vaccination approaches: en route to protect newborns? FEMS Immunol. Med. Microbiol. 66, 121-133 (2012).
25. Mattoo, S. & Cherry, J. D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18, 326-382 (2005). (Pubitemid 40548297)
26. Weiss, A. A., Hewlett, E. L., Myers, G. A. & Falkow, S. Tn5-induced mutations affecting virulence factors of Bordetella pertussis. Infect. Immun. 42, 33-41 (1983). (Pubitemid 13012431)
27. Weiss, A. A., Melton, A. R., Walker, K. E., Andraos-Selim, C. & Meidl, J. J. Use of the promoter fusion transposon Tn5 lac to identify mutations in Bordetella pertussis vir-regulated genes. Infect. Immun. 57, 2674-2682 (1989). (Pubitemid 19212597)
28. Knapp, S. & Mekalanos, J. J. Tw o trans-acting regulatory genes (vir and mod) control antigenic modulation in Bordetella pertussis. J. Bacteriol. 170, 5059-5066 (1988). (Pubitemid 18259454)
29. Cummings, C. A., Bootsma, H. J., Relman, D. A. & Miller, J. F. Species-and strain-specific control of a complex, flexible regulon by Bordetella BvgAS. J. Bacteriol. 188, 1775-1785 (2006). (Pubitemid 43346856)
30. Nicholson, T. L. Construction and validation of a first-generation Bordetella bronchiseptica long-oligonucleotide microarray by transcriptional profiling the Bvg regulon. BMC Genomics 8, 220 (2007).
31. Herrou, J. et al. Periplasmic domain of the sensor-kinase BvgS reveals a new paradigm for the Venus flytrap mechanism. Proc. Natl Acad. Sci. USA 107, 17351-17355 (2010).
32. Uhl, M. A. & Miller, J. F. Autophosphorylation and phosphotransfer in the Bordetella pertussis BvgAS signal transduction cascade. Proc. Natl Acad. Sci. USA 91, 1163-1167 (1994). (Pubitemid 24048529)
33. Boucher, P. E., Maris, A. E., Yang, M. S. & Stibitz, S. The response regulator BvgA and RNA polymerase α subunit C-terminal domain bind simultaneously to different faces of the same segment of promoter DNA. Mol. Cell 11, 163-173 (2003). (Pubitemid 36126598)
34. Boucher, P. E., Murakami, K., Ishihama, A. & Stibitz, S. Nature of DNA binding and RNA polymerase interaction of the Bordetella pertussis BvgA transcriptional activator at the fha promoter. J. Bacteriol. 179, 1755-1763 (1997). (Pubitemid 27100467)
35. Stockbauer, K. E., Fuchslocher, B., Miller, J. F. & Cotter, P. A. Identification and characterization of BipA, a Bordetella Bvg-intermediate phase protein. Mol. Microbiol. 39, 65-78 (2001). (Pubitemid 32057677)
36. Deora, R., Bootsma, H. J., Miller, J. F. & Cotter, P. A. Diversity in the Bordetella virulence regulon: transcriptional control of a Bvg-intermediate phase gene. Mol. Microbiol. 40, 669-683 (2001). (Pubitemid 32453119)
37. Cotter, P. A. & Miller, J. F. BvgAS-mediated signal transduction: analysis of phase-locked regulatory mutants of Bordetella bronchiseptica in a rabbit model. Infect. Immun. 62, 3381-3390 (1994). (Pubitemid 24232124)
38. Merkel, T. J., Stibitz, S., Keith, J. M., Leef, M. & Shahin, R. Contribution of regulation by the bvg locus to respiratory infection of mice by Bordetella pertussis. Infect. Immun. 66, 4367-4373 (1998). (Pubitemid 28402713)
39. Akerley, B. J., Cotter, P. A. & Miller, J. F. Ectopic expression of the flagellar regulon alters development of the Bordetella-host interaction. Cell 80, 611-620 (1995).
40. Martinez de Tejada, G. et al. Neither the Bvg-phase nor the vrg6 locus of Bordetella pertussis is required for respiratory infection in mice. Infect. Immun. 66, 2762-2768 (1998).
41. Veal-Carr, W. L. & Stibitz, S. Demonstration of differential virulence gene promoter activation in vivo in Bordetella pertussis using RIVET. Mol. Microbiol. 55, 788-798 (2005). (Pubitemid 40203694)
42. Byrd, M. S., Mason, E., Henderson, M. W., Scheller, E. V. & Cotter, P. A. An improved recombination-based in vivo expression technologylike reporter system reveals differential cyaA gene activation in Bordetella species. Infect. Immun. 81, 1295-1305 (2013).
43. Porter, J. F., Parton, R. & Wardlaw, A. C. Growth and survival of Bordetella bronchiseptica in natural waters and in buffered saline without added nutrients. Appl. Environ. Microbiol. 57, 1202-1206 (1991).
44. Morse, S. I. & Morse, J. H. Isolation and properties of the leukocytosis-and lymphocytosis-promoting factor of Bordetella pertussis. J. Exp. Med. 143, 1483-1502 (1976).
45. Pittman, M. The concept of pertussis as a toxin-mediated disease. Pediatr. Infect. Dis. 3, 467-486 (1984). (Pubitemid 14044510)
46. Locht, C., Antoine, R. & Jacob-Dubuisson, F. Bordetella pertussis, molecular pathogenesis under multiple aspects. Curr. Opin. Microbiol. 4, 82-89 (2001). (Pubitemid 32126902)
47. Stein, P. E. et al. The crystal structure of pertussis toxin. Structure 2, 45-57 (1994).
48. Kotob, S. I., Hausman, S. Z. & Burns, D. L. Localization of the promoter for the ptl genes of Bordetella pertussis, which encode proteins essential for secretion of pertussis toxin. Infect. Immun. 63, 3227-3230 (1995).
49. Stein, P. E. et al. Structure of a pertussis toxin-sugar complex as a model for receptor binding. Nature Struct. Biol. 1, 591-596 (1994).
50. El Baya, A., Bruckener, K. & Schmidt M. A. Nonrestricted differential intoxication of cells by pertussis toxin. Infect. Immun. 67, 433-435 (1999). (Pubitemid 29021683)
51. Worthington, Z. E. & Carbonetti, N. H. Evading the proteasome: absence of lysine residues contributes to pertussis toxin activity by evasion of proteasome degradation. Infect. Immun. 75, 2946-2953 (2007). (Pubitemid 46870176)
52. Graf, R., Codina, J. & Birnbaumer, L. Peptide inhibitors of ADP-ribosylation by pertussis toxin are substrates with affinities comparable to those of the trimeric GTP-binding proteins. Mol. Pharmacol. 42, 760-764 (1992). (Pubitemid 23021478)
53. Spangrude, G. J., Sacchi, F., Hill, H. R., Van Epps, D. E. & Daynes, R. A. Inhibition of lymphocyte and neutrophil chemotaxis by pertussis toxin. J. Immunol. 135, 4135-4143 (1985). (Pubitemid 16250403)
54. Andreasen, C. & Carbonetti, N. H. Pertussis toxin inhibits early chemokine production to delay neutrophil recruitment in response to Bordetella pertussis respiratory tract infection in mice. Infect. Immun. 76, 5139-5148 (2008).
55. Kirimanjeswara, G. S., Agosto, L. M., Kennett, M. J., Bjornstad, O. N. & Harvill, E. T. Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J. Clin. Invest. 115, 3594-3601 (2005). (Pubitemid 43121848)
56. Carbonetti, N. H., Artamonova, G. V., Van Rooijen, N. & Ayala, V. I. Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract. Infect. Immun. 75, 1713-1720 (2007). (Pubitemid 46559436)
57. Connelly, C. E., Sun, Y. & Carbonetti, N. H. Pertussis toxin exacerbates and prolongs airway inflammatory responses during Bordetella pertussis infection. Infect. Immun. 80, 4317-4332 (2012).
58. Mu, H. H., Cooley, M. A. & Sewell, W. A. Studies on the lymphocytosis induced by pertussis toxin. Immunol. Cell Biol. 72, 267-270 (1994). (Pubitemid 24199694)
59. Bruss, J. B. et al. Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin. Pediatr. Infect. Dis. J. 18, 505-511 (1999). (Pubitemid 29277613)
60. Glaser, P., Danchin, A., Ladant, D., Barzu, O. & Ullmann, A. Bordetella pertussis adenylate cyclase: the gene and the protein. Tokai J. Exp. Clin. Med. 13 (Suppl.), 239-252 (1988). (Pubitemid 20128249)
61. Hackett M., Guo L, Shabanowitz, J., Hunt, D. F. & Hewlett, E. L. Internal lysine palmitoylation in adenylate cyclase toxin from Bordetella pertussis. Science 266, 433-435 (1994). (Pubitemid 24348962)
62. El-Azami-El-Idrissi, M. et al. Interaction of Bordetella pertussis adenylate cyclase with CD11b/CD18: role of toxin acylation and identification of the main integrin interaction domain. J. Biol. Chem. 278, 38514-38521 (2003). (Pubitemid 37221746)
63. Sakamoto, H., Bellalou, J., Sebo, P. & Ladant, D. Bordetella pertussis adenylate cyclase toxin. Structural and functional independence of the catalytic and hemolytic activities. J. Biol. Chem. 267, 13598-13602 (1992).
64. Ladant, D. et al. Characterization of the calmodulin-binding and of the catalytic domains of Bordetella pertussis adenylate cyclase. J. Biol. Chem. 264, 4015-4020 (1989). (Pubitemid 19072291)
65. Glaser, P. et al. Identification of residues essential for catalysis and binding of calmodulin in Bordetella pertussis adenylate cyclase by site-directed mutagenesis. EMBO J. 8, 967-972 (1989). (Pubitemid 19273264)
66. Fiser, R. et al. Calcium influx rescues adenylate cyclase-hemolysin from rapid cell membrane removal and enables phagocyte permeabilization by toxin pores. PLoS Pathog. 8, e1002580 (2012).
67. M(L integrin (CD11b/CD18). J. Exp. Med. 193, 1035-1044 (2001). (Pubitemid 32436197)
68. Confer, D. L. & Eaton, J. W. Phagocyte impotence caused by an invasive bacterial adenylate cyclase. Science 217, 948-950 (1982). (Pubitemid 12047357)
69. Kamanova, J. et al. Adenylate cyclase toxin subverts phagocyte function by RhoA inhibition and unproductive ruffling. J. Immunol. 181, 5587-5597 (2008).
70. Paccani, S. R. et al. Suppression of T-lymphocyte activation and chemotaxis by the adenylate cyclase toxin of Bordetella pertussis. Infect. Immun. 76, 2822-2832 (2008).
71. Eby, J. C. et al. Quantification of the adenylate cyclase toxin of Bordetella pertussis in vitro and during respiratory infection. Infect. Immun. 81, 1390-1398 (2013).
72. Harvill, E. T., Cotter, P. A., Yuk, M. H. & Miller, J. F Probing the function of Bordetella bronchiseptica adenylate cyclase toxin by manipulating host immunity. Infect. Immun. 67, 1493-1500 (1999). (Pubitemid 29108533)
73. Henderson, M. W. et al. Contribution of Bordetella filamentous hemagglutinin and adenylate cyclase toxin to suppression and evasion of interleukin-17-mediated inflammation. Infect. Immun. 80, 2061-2075 (2012).
74. Villarino Romero, R. et al. The Bordetella pertussis type III secretion system tip complex protein Bsp22 is not a protective antigen and fails to elicit serum antibody responses during infection of humans and mice. Infect. Immun. 81, 2761-2767 (2013).
75. Stockbauer, K. E., Foreman-Wykert, A. K. & Miller, J. F. Bordetella type III secretion induces caspase 1-independent necrosis. Cell. Microbiol. 5, 123-132 (2003). (Pubitemid 36395126)
76. Yuk, M. H., Harvill, E. T., Cotter, P. A. & Miller, J. F. Modulation of host immune responses, induction of apoptosis and inhibition of NF-κB activation by the Bordetella type III secretion system. Mol. Microbiol. 35, 991-1004 (2000). (Pubitemid 30137770)
77. Yuk, M. H., Harvill, E. T. & Miller, J. F. The BvgAS virulence control system regulates type III secretion in Bordetella bronchiseptica. Mol. Microbiol. 28, 945-959 (1998). (Pubitemid 28258992)
78. Skinner, J. A., Pilione, M. R., Shen, H., Harvill, E. T. & Yuk, M. H. Bordetella type III secretion modulates dendritic cell migration resulting in immunosuppression and bacterial persistence. J. Immunol. 175, 4647-4652 (2005). (Pubitemid 41362005)
79. Panina, E. M. et al. A genome-wide screen identifies a Bordetella type III secretion effector and candidate effectors in other species. Mol. Microbiol. 58, 267-279 (2005). (Pubitemid 41415046)
80. Kuwae, A. et al. BopC is a novel type III effector secreted by Bordetella bronchiseptica and has a critical role in type III-dependent necrotic cell death. J. Biol. Chem. 281, 6589-6600 (2006). (Pubitemid 43847593)
81. Nagamatsu, K. et al. Bordetella evades the host immune system by inducing IL-10 through a type III effector, BopN. J. Exp. Med. 206, 3073-3088 (2009).
82. French, C. T. et al. The Bordetella type III secretion system effector BteA contains a conserved N-terminal motif that guides bacterial virulence factors to lipid rafts. Cell. Microbiol. 11, 1735-1749 (2009).
83. Mattoo, S., Yuk, M. H., Huang, L. L. & Miller, J. F. Regulation of type III secretion in Bordetella. Mol. Microbiol. 52, 1201-1214 (2004). (Pubitemid 38916184)
84. Brickman, T. J., Cummings, C. A., Liew, S. Y., Relman, D. A. & Armstrong, S. K. Transcriptional profiling of the iron starvation response in Bordetella pertussis provides new insights into siderophore utilization and virulence gene expression. J. Bacteriol. 193, 4798-4812 (2011).
85. Kozak, N. A., Mattoo, S., Foreman-Wykert, A. K., Whitelegge, J. P. & Miller, J. F. Interactions between partner switcher orthologs BtrW and BtrV regulate type III secretion in Bordetella. J. Bacteriol. 187, 5665-5676 (2005). (Pubitemid 41134302)
86. Fennelly, N. K. et al. Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect. Immun. 76, 1257-1266 (2008). (Pubitemid 351428089)
87. Gaillard, M. E., Bottero, D., Castuma, C. E., Basile, L. A. & Hozbor, D. Laboratory adaptation of Bordetella pertussis is associated with the loss of type three secretion system functionality. Infect. Immun. 79, 3677-3682 (2011).
88. Cookson, B. T., Tyler, A. N. & Goldman, W. E. Primary structure of the peptidoglycan-derived tracheal cytotoxin of Bordetella pertussis. Biochemistry 28, 1744-1749 (1989). (Pubitemid 19072048)
89. Goodell, E. W. & Schwarz, U. Release of cell wall peptides into culture medium by exponentially growing Escherichia coli. J. Bacteriol. 162, 391-397 (1985). (Pubitemid 15095880)
90. Park, J. T. Turnover and recycling of the murein sacculus in oligopeptide permease-negative strains of Escherichia coli: indirect evidence for an alternative permease system and for a monolayered sacculus. J. Bacteriol. 175, 7-11 (1993). (Pubitemid 23016644)
91. Flak, T. A. & Goldman, W. E. Signalling and cellular specificity of airway nitric oxide production in pertussis. Cell. Microbiol. 1, 51-60 (1999). (Pubitemid 129667952)
92. Heiss, L. N., Moser, S. A., Unanue, E. R. & Goldman, W. E. Interleukin-1 is linked to the respiratory epithelial cytopathology of pertussis. Infect. Immun. 61, 3123-3128 (1993). (Pubitemid 23223395)
93. Magalhaes, J. G. et al. Murine Nod1 but not its human orthologue mediates innate immune detection of tracheal cytotoxin. EMBO Rep. 6, 1201-1207 (2005). (Pubitemid 41741706)
94. Cowell, J. L., Hewlett, E. L. & Manclark, C. R. Intracellular localization of the dermonecrotic toxin of Bordetella pertussis. Infect. Immun. 25, 896-901 (1979). (Pubitemid 9251892)
95. Brockmeier, S. L. et al. Role of the dermonecrotic toxin of Bordetella bronchiseptica in the pathogenesis of respiratory disease in swine. Infect. Immun. 70, 481-490 (2002). (Pubitemid 34083804)
96. Horiguchi, Y. et al. Bordetella bronchiseptica dermonecrotizing toxin induces reorganization of actin stress fibers through deamidation of Gln-63 of the GTP-binding protein Rho. Proc. Natl Acad. Sci. USA 94, 11623-11626 (1997).
97. Schmidt, G., Goehring, U. M., Schirmer, J., Lerm, M. & Aktories, K. Identification of the C-terminal part of Bordetella dermonecrotic toxin as a transglutaminase for rho GTPases. J. Biol. Chem. 274, 31875-31881 (1999).
98. Horiguchi, Y. et al. Effects of Bordetella bronchiseptica dermonecrotizing toxin on bone formation in calvaria of neonatal rats. FEMS Immunol. Med. Microbiol. 12, 29-32 (1995).
99. Horiguchi, Y., Nakai, T. & Kume, K. Effects of Bordetella bronchiseptica dermonecrotic toxin on the structure and function of osteoblastic clone MC3T3-e1 cells. Infect. Immun. 59, 1112-1116 (1991).
100. Nakai, T., Sawata, A. & Kume, K. Intracellular locations of dermonecrotic toxins in Pasteurella multocida and in Bordetella bronchiseptica. Am. J. Vet. Res. 46, 870-874 (1985). (Pubitemid 15101389)
101. Leo, J. C., Grin, I. & Linke, D. Type V secretion: mechanism(s) of autotransport through the bacterial outer membrane. Phil. Trans. R. Soc. B 367, 1088-1101 (2012).
102. Mazar, J. & Cotter, P. A. New insight into the molecular mechanisms of two-partner secretion. Trends Microbiol. 15, 508-515 (2007). (Pubitemid 350102190)
103. Coutte, L., Antoine, R., Drobecq, H., Locht, C. & Jacob-Dubuisson, F. Subtilisin-like autotransporter serves as maturation protease in a bacterial secretion pathway. EMBO J. 20, 5040-5048 (2001). (Pubitemid 32910900)
104. Mazar, J. & Cotter, P. A. Topology and maturation of filamentous haemagglutinin suggest a new model for two-partner secretion. Mol. Microbiol. 62, 641-654 (2006). (Pubitemid 44571591)
105. Alonso, S., Pethe, K., Mielcarek, N., Raze, D. & Locht, C. Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection. Infect. Immun. 69, 6038-6043 (2001). (Pubitemid 32885163)
106. Inatsuka, C. S., Julio, S. M. & Cotter, P. A. Bordetella filamentous hemagglutinin plays a critical role in immunomodulation, suggesting a mechanism for host specificity. Proc. Natl Acad. Sci. USA 102, 18578-18583 (2005). (Pubitemid 43011268)
107. Funnell, S. G. & Robinson, A. A novel adherence assay for Bordetella pertussis using tracheal organ cultures. FEMS Microbiol. Lett. 110, 197-203 (1993).
108. Van Strijp, J. A., Russell, D. G., Tuomanen, E., Brown, E. J. & Wright, S. D. Ligand specificity of purified complement receptor type three (CD11b/CD18, αMβ2, Mac-1). Indirect effects of an Arg-Gly-Asp (RGD) sequence. J. Immunol. 151, 3324-3336 (1993). (Pubitemid 23282645)
109. Ishibashi, Y. et al. Role of phosphatidylinositol 3-kinase in the binding of Bordetella pertussis to human monocytes. Cell. Microbiol. 4, 825-833 (2002). (Pubitemid 35469670)
110. Ishibashi, Y. & Nishikawa, A. Bordetella pertussis infection of human respiratory epithelial cells up-regulates intercellular adhesion molecule-1 expression: role of filamentous hemagglutinin and pertussis toxin. Microb. Pathog. 33, 115-125 (2002).
111. Julio, S. M. et al. Natural-host animal models indicate functional interchangeability between the filamentous haemagglutinins of Bordetella pertussis and Bordetella bronchiseptica and reveal a role for the mature C-terminal domain, but not the RGD motif, during infection. Mol. Microbiol. 71, 1574-1590 (2009).
112. Nicholson, T. L., Brockmeier, S. L. & Loving, C. L. Contribution of Bordetella bronchiseptica filamentous hemagglutinin and pertactin to respiratory disease in swine. Infect. Immun. 77, 2136-2146 (2009).
113. Gray, M. C., Donato, G. M., Jones, F. R., Kim, T. & Hewlett, E. L. Newly secreted adenylate cyclase toxin is responsible for intoxication of target cells by Bordetella pertussis. Mol. Microbiol. 53, 1709-1719 (2004). (Pubitemid 39265316)
114. Willems, R. J., van der Heide, H. G. & Mooi, F. R. Characterization of a Bordetella pertussis fimbrial gene cluster which is located directly downstream of the filamentous haemagglutinin gene. Mol. Microbiol. 6, 2661-2671 (1992).
115. Willems, R., Paul, A., van der Heide, H. G., ter Avest, A. R. & Mooi, F. R. Fimbrial phase variation in Bordetella pertussis: a novel mechanism for transcriptional regulation. EMBO J. 9, 2803-2809 (1990).
116. Kania, S. A. et al. Characterization of fimN, a new Bordetella bronchiseptica major fimbrial subunit gene. Gene 256, 149-155 (2000).
117. Pedroni, P. et al. Cloning of a novel pilin-like gene from Bordetella pertussis: homology to the fim2 gene. Mol. Microbiol. 2, 539-543 (1988).
118. Boschwitz, J. S., van der Heide, H. G., Mooi, F. R. & Relman, D. A. Bordetella bronchiseptica expresses the fimbrial structural subunit gene fimA. J. Bacteriol. 179, 7882-7885 (1997). (Pubitemid 27525723)
119. Hazenbos, W. L., van den Berg, B. M., van't Wout, J. W., Mooi, F. R. & van Furth, R. Virulence factors determine attachment and ingestion of nonopsonized and opsonized Bordetella pertussis by human monocytes. Infect. Immun. 62, 4818-4824 (1994). (Pubitemid 24332781)
120. Mattoo, S., Miller, J. F. & Cotter, P. A. Role of Bordetella bronchiseptica fimbriae in tracheal colonization and development of a humoral immune response. Infect. Immun. 68, 2024-2033 (2000). (Pubitemid 30164833)
121. Geuijen, C. A. et al. Role of the Bordetella pertussis minor fimbrial subunit, FimD, in colonization of the mouse respiratory tract. Infect. Immun. 65, 4222-4228 (1997). (Pubitemid 27422081)
122. Vandebriel, R. J. et al. Association of Bordetella pertussis with host immune cells in the mouse lung. Microb. Pathog. 35, 19-29 (2003). (Pubitemid 36809186)
123. Henderson, I. R., Navarro-Garcia, F., Desvaux, M., Fernandez, R. C. & Ala'Aldeen, D. Type V protein secretion pathway: the autotransporter story. Microbiol. Mol. Biol. Rev. 68, 692-744 (2004). (Pubitemid 39628534)
124. Emsley, P., Charles, I. G., Fairweather, N. F. & Isaacs, N. W. Structure of Bordetella pertussis virulence factor P.69 pertactin. Nature 381, 90-92 (1996). (Pubitemid 26130010)
125. Inatsuka, C. S. et al. Pertactin is required for Bordetella species to resist neutrophil-mediated clearance. Infect. Immun. 78, 2901-2909 (2010).
126. Khelef, N., Bachelet, C. M., Vargaftig, B. B. & Guiso, N. Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins. Infect. Immun. 62, 2893-2900 (1994). (Pubitemid 24203975)
127. Pawloski, L. C. et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the US. Clin. Vaccine Immunol. 21, 119-125 (2013).
128. Allen, A. G., Thomas, R. M., Cadisch, J. T. & Maskell, D. J. Molecular and functional analysis of the lipopolysaccharide biosynthesis locus wlb from Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Mol. Microbiol. 29, 27-38 (1998). (Pubitemid 28318560)
129. Caroff, M. et al. Structural variability and originality of the Bordetella endotoxins. J. Endotoxin Res. 7, 63-68 (2001). (Pubitemid 32496462)
130. Preston, A. et al. Complete structures of Bordetella bronchiseptica and Bordetella parapertussis lipopolysaccharides. J. Biol. Chem. 281, 18135-18144 (2006). (Pubitemid 44035613)
131. Preston, A. et al. Genetic basis for lipopolysaccharide O-antigen biosynthesis in bordetellae. Infect. Immun. 67, 3763-3767 (1999). (Pubitemid 29356989)
132. Preston, A. et al. Bordetella bronchiseptica PagP is a Bvg-regulated lipid A palmitoyl transferase that is required for persistent colonization of the mouse respiratory tract. Mol. Microbiol. 48, 725-736 (2003) (Pubitemid 36819058)
133. Burns, V. C., Pishko, E. J., Preston, A., Maskell, D. J. & Harvill, E. T. Role of Bordetella O antigen in respiratory tract infection. Infect. Immun. 71, 86-94 (2003). (Pubitemid 36026007)
134. Mann, P. B., Elder, K. D., Kennett, M. J. & Harvill, E. T. Toll-like receptor 4-dependent early elicited tumor necrosis factor α expression is critical for innate host defense against Bordetella bronchiseptica. Infect. Immun. 72, 6650-6658 (2004). (Pubitemid 39425448)
135. Mann, P. B., Kennett, M. J. & Harvill, E. T. Toll-like receptor 4 is critical to innate host defense in a murine model of bordetellosis. J. Infect. Dis. 189, 833-836 (2004). (Pubitemid 38328184)
136. Higgins, S. C. et al. Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J. Immunol. 171, 3119-3127 (2003). (Pubitemid 37093535)
137. Mann, P. B. et al. Comparative toll-like receptor 4-mediated innate host defense to Bordetella infection. Infect. Immun. 73, 8144-8152 (2005). (Pubitemid 41740302)
138. Banus, H. A. et al. Host genetics of Bordetella pertussis infection in mice: significance of Toll-like receptor 4 in genetic susceptibility and pathobiology. Infect. Immun. 74, 2596-2605 (2006). (Pubitemid 43672967)
139. Hajjar, A. M., Ernst, R. K., Tsai, J. H., Wilson, C. B. & Miller, S. I. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nature Immunol. 3, 354-359 (2002). (Pubitemid 34308623)
140. Marr, N. et al. Substitution of the Bordetella pertussis lipid A phosphate groups with glucosamine is required for robust NF-κB activation and release of proinflammatory cytokines in cells expressing human but not murine Toll-like receptor 4-MD-2-CD14. Infect. Immun. 78, 2060-2069 (2010).
141. Marr, N., Tirsoaga, A., Blanot, D., Fernandez, R. & Caroff, M. Glucosamine found as a substituent of both phosphate groups in Bordetella lipid A backbones: role of a BvgAS-activated ArnT ortholog. J. Bacteriol. 190, 4281-4290 (2008). (Pubitemid 351812875)
142. Hot, D. et al. Differential modulation of Bordetella pertussis virulence genes as evidenced by DNA microarray analysis. Mol. Genet. Genom. 269, 475-486 (2003). (Pubitemid 36976155)
143. Bokhari, H., Bilal, I. & Zafar, S. BapC autotransporter protein of Bordetella pertussis is an adhesion factor. J. Bas. Microbiol. 52, 390-396 (2012).
144. Marr, N., Shah, N. R., Lee, R., Kim, E. J. & Fernandez, R. C. Bordetella pertussis autotransporter Vag8 binds human C1 esterase inhibitor and confers serum resistance. PLoS ONE 6, e20585 (2011).
145. Middendorf, B. et al. Phg, a novel member of the autotransporter family present in Bordetella species. Microbiol. Res. 160, 329-336 (2005). (Pubitemid 40793853)
146. Finn, T. M. & Stevens, L. A. Tracheal colonization factor: a Bordetella pertussis secreted virulence determinant. Mol. Microbiol. 16, 625-634 (1995).
147. Marr, N. et al. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model. Vaccine 26, 4306-4311 (2008).
148. Williams, C. L., Haines, R. & Cotter, P. A. Serendipitous discovery of an immunoglobulin-binding autotransporter in Bordetella species. Infect. Immun. 76, 2966-2977 (2008).
149. Sukumar, N., Mishra, M., Sloan, G. P., Ogi, T. & Deora, R. Differential Bvg phase-dependent regulation and combinatorial role in pathogenesis of two Bordetella paralogs, BipA and BcfA. J. Bacteriol. 189, 3695-3704 (2007). (Pubitemid 46740166)
150. Sukumar, N. et al. Active and passive immunizations with Bordetella colonization factor A protect mice against respiratory challenge with Bordetella bronchiseptica. Infect. Immun. 77, 885-895 (2009).
151. Moore, C. H. et al. Identification of alcaligin as the siderophore produced by Bordetella pertussis and B. bronchiseptica. J. Bacteriol. 177, 1116-1118 (1995).
152. Beall, B. & Hoenes, T. An iron-regulated outer-membrane protein specific to Bordetella bronchiseptica and homologous to ferric siderophore receptors. Microbiology 143, 135-145 (1997). (Pubitemid 27072968)
153. Mocny, J. C., Olson, J. S. & Connell, T. D. Passively released heme from hemoglobin and myoglobin is a potential source of nutrient iron for Bordetella bronchiseptica. Infect. Immun. 75, 4857-4866 (2007). (Pubitemid 47502156)
154. Brickman, T. J., Vanderpool, C. K. & Armstrong, S. K. Heme transport contributes to in vivo fitness of Bordetella pertussis during primary infection in mice. Infect. Immun. 74, 1741-1744 (2006). (Pubitemid 43346808)
155. Brickman, T. J. & Armstrong, S. K. Impact of alcaligin siderophore utilization on in vivo growth of Bordetella pertussis. Infect. Immun. 75, 5305-5312 (2007). (Pubitemid 350033618)
156. Irie, Y., Mattoo, S. & Yuk, M. H. The Bvg virulence control system regulates biofilm formation in Bordetella bronchiseptica. J. Bacteriol. 186, 5692-5698 (2004). (Pubitemid 39128641)
157. Irie, Y., Preston, A. & Yuk, M. H. Expression of the primary carbohydrate component of the Bordetella bronchiseptica biofilm matrix is dependent on growth phase but independent of Bvg regulation. J. Bacteriol. 188, 6680-6687 (2006). (Pubitemid 44418870)
158. Conover, M. S. et al. BpsR modulates Bordetella biofilm formation by negatively regulating the expression of the Bps polysaccharide. J. Bacteriol. 194, 233-242 (2012).
159. Nicholson, T. L., Conover, M. S. & Deora, R. Transcriptome profiling reveals stage-specific production and requirement of flagella during biofilm development in Bordetella bronchiseptica. PLoS ONE 7, e49166 (2012).
160. Parise, G., Mishra, M., Itoh, Y., Romeo, T. & Deora, R. Role of a putative polysaccharide locus in Bordetella biofilm development. J. Bacteriol. 189, 750-760 (2007). (Pubitemid 46183849)
161. Conover, M. S., Mishra, M. & Deora, R. Extracellular DNA is essential for maintaining Bordetella biofilm integrity on abiotic surfaces and in the upper respiratory tract of mice. PLoS ONE 6, e16861 (2011).
162. Sisti, F., Ha, D. G., O'Toole, G. A., Hozbor, D. & Fernandez, J. Cyclic-di-GMP signalling regulates motility and biofilm formation in Bordetella bronchiseptica. Microbiology 159, 869-879 (2013)
163. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2012. Reporting on 2010 surveillance data and 2011 epidemic intelligence data (ECDC, 2013).
164. Fingermann, M. et al. Differences of circulating Bordetella pertussis population in Argentina from the strain used in vaccine production. Vaccine 24, 3513-3521 (2006).
165. Warfel, J. M., Zimmerman, L. I. & Merkel, T. J. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc. Natl Acad. Sci. USA (2013).
166. Feunou, P. F., Kammoun, H., Debrie, A. S., Mielcarek, N. & Locht, C. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine 28, 7047-7053 (2010).
167. Dias, W. O. et al. An improved whole cell pertussis vaccine with reduced content of endotoxin. Hum. Vaccines Immunother. 9, 339-348 (2012).
168. Vitek, C. R., Pascual, F. B., Baughman, A. L. & Murphy, T. V. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr. Infect. Dis. J. 22, 628-634 (2003). (Pubitemid 36900210)
169. Pillay, V. & Swingler, G. Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst. Rev. 5, CD003257 (2003).
170. Rowlands, H. E. et al. Impact of rapid leukodepletion on the outcome of severe clinical pertussis in young infants. Pediatrics 126, e816-827 (2010).
171. Sawal, M. et al. Fulminant pertussis: a multi-center study with new insights into the clinico-pathological mechanisms. Pediatr. Pulmonol. 44, 970-980 (2009).
172. Musser, J. M., Hewlett, E. L., Peppler, M. S. & Selander, R. K. Genetic diversity and relationships in populations of Bordetella spp. J. Bacteriol. 166, 230-237 (1986). (Pubitemid 16043305)
173. van der Zee, A., Mooi, F., Van Embden, J. & Musser, J. Molecular evolution and host adaptation of Bordetella spp.: phylogenetic analysis using multilocus enzyme electrophoresis and typing with three insertion sequences. J. Bacteriol. 179, 6609-6617 (1997). (Pubitemid 27465292)
174. Preston, A., Parkhill, J. & Maskell, D. J. The bordetellae: lessons from genomics. Nature Rev. Microbiol. 2, 379-390 (2004). (Pubitemid 39490117)
175. Parkhill, J. et al. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nature Genet. 35, 32-40 (2003). (Pubitemid 37048593)
176. Mooi, F. R., van der Maas. N. A. & De Melker, H. E. Pertussis resurgence: waning immunity and pathogen adaptation-two sides of the same coin. Epidemiol. Infect. 13, 1-10 (2013).
177. Bart, M. J. et al. Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics 11, 627 (2010).
178. Schmidtke, A. J. et al. Population diversity among Bordetella pertussis isolates, United States, 1935-2009. Emerg. Infect. Dis. 18, 1248-1255 (2012).
179. Mooi, F. R. et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg. Infect. Dis. 15, 1206-1213 (2009).
180. Mooi, F. R. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect. Genet. Evol. 10, 36-49 (2010).
181. Elahi, S. et al. Infection of newborn piglets with Bordetella pertussis: a new model for pertussis. Infect. Immun. 73, 3636-3645 (2005). (Pubitemid 40745908)
182. Elahi, S., Buchanan, R. M., Babiuk, L. A. & Gerdts, V. Maternal immunity provides protection against pertussis in newborn piglets. Infect. Immun. 74, 2619-2627 (2006). (Pubitemid 43672970)
183. ACOG Committee. Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Obstet. Gynecol. 121, 1411-1414 (2013).
184. Terranella, A., Asay, G. R., Messonnier, M. L., Clark, T. A. & Liang, J. L. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis. Pediatrics 131, e1748-1756 (2013).
185. Elahi, S. et al. Infection with Bordetella parapertussis but not Bordetella pertussis causes pertussis-like disease in older pigs. J. Infect. Dis. 198, 384-392 (2008).
186. Warfel, J. M., Beren, J., Kelly, V. K., Lee, G. & Merkel, T. J. Nonhuman primate model of pertussis. Infect. Immun. 80, 1530-1536 (2012).
187. Warfel, J. M., Beren, J. & Merkel, T. J. Airborne transmission of Bordetella pertussis. J. Infect. Dis. 206, 902-906 (2012).
188. Egberink, H. et al. Bordetella bronchiseptica infection in cats. ABCD guidelines on prevention and management. J. Feline Med. Surg. 11, 610-614 (2009).
189. Mochizuki, M., Yachi, A., Ohshima, T., Ohuchi, A. & Ishida, T. Etiologic study of upper respiratory infections of household dogs. J. Vet. Med. Sci. 70, 563-569 (2008). (Pubitemid 352008823)
190. Woolfrey, B. F. & Moody, J. A. Human infections associated with Bordetella bronchiseptica. Clin. Microbiol. Rev. 4, 243-255 (1991). (Pubitemid 21920398)
191. Martinez de Tejada, G., Miller, J. F. & Cotter, P. A. Comparative analysis of the virulence control systems of Bordetella pertussis and Bordetella bronchiseptica. Mol. Microbiol. 22, 895-908 (1996). (Pubitemid 26411334)
192. Miller, D., Madge, N., Diamond, J., Wadsworth, J. & Ross, E. Pertussis immunisation and serious acute neurological illnesses in children. BMJ 307, 1171-1176 (1993). (Pubitemid 23319334)
193. Mascart, F. et al. Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J. Immunol. 170, 1504-1509 (2003). (Pubitemid 36139521)
194. Giammanco, A. et al. Analogous IgG subclass response to pertussis toxin in vaccinated children, healthy or affected by whooping cough. Vaccine 21, 1924-1931 (2003). (Pubitemid 36428782)
195. Guiso, N. et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 25, 1390-1397 (2007). (Pubitemid 46091822)
196. Schure, R. M. et al. T-cell responses before and after the fifth consecutive acellular pertussis vaccination in 4-year-old Dutch children. Clin. Vaccine Immunol. 19, 1879-1886 (2012).
197. Mascart, F. et al. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 25, 391-398 (2007). (Pubitemid 44873143)
198. Vermeulen, F. et al. Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines. Clin. Vaccine Immunol. 17, 258-262 (2010).
199. Warfel, J. M. & Merkel, T. J. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol. 6, 787-796 (2013).